Sema4: Eli Casdin, Emily Leproust, Jason Ryan, Nat Turner

Jul 23, 2021

As part of its merger with special purpose acquisition company CM Life Sciences, Sema4 has appointed four new directors to its board: Eli Casdin, chief investment officer of Casdin Capital; Emily Leproust, CEO of Twist Bioscience; Jason Ryan, former chief operating officer and CFO of Magenta Therapeutics and former CFO of Foundation Medicine; and Nat Turner, cofounder of Flatiron Health.

Breaking News

Plasmid Transfer Let Cholera Pathogen in Yemen Become Multidrug Resistant, Study Suggests
Harbinger Health Raises $140 Million in Series B Financing
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
Genetic Overlap Between Schizophrenia, Cardiovascular Disease Risk Uncovered by GWAS Analysis

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.